Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
November 14, 2018
Neovasc Announces Third Quarter 2018 Financial Results
VANCOUVER , Nov. 14, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN TSX: NVCN), a leader in the development of minimally invasive ...
November 14, 2018
AIT Therapeutics Reports Financial Results for Fiscal Second Quarter 2019
GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 14, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
November 14, 2018
CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update
MENLO PARK, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
November 14, 2018
Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update
FREMONT,Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced financial results for the ...
November 14, 2018
Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous ...
November 14, 2018
EDAP TMS SA : EDAP Reports 2018 Third Quarter Results
LYON, France, November 14, 2018 -- EDAP TMS SA (EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today financial results for the third ...
November 5, 2018
Genkyotex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX) announced today that its lead product candidate GKT831, a NOX1/4 inhibitor, met both the primary ...
November 5, 2018
Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNATM, a First-In-Class DNA Damage Response Inhibitor
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response ...
November 5, 2018
Check-Cap Reports Third Quarter 2018 Financial Results
ISFIYA, Israel, Nov. 5, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, ...
November 5, 2018
Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
BOSTON and LONDON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious ...
November 5, 2018
UroGen Pharma to Report Third Quarter 2018 Financial Results on Monday, November 12, 2018
RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (URGN) today announced that it will report third quarter 2018 financial results on Monday, November 12, 2018, ...
November 5, 2018
Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update
PITTSBURGH, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech (KRYS), a gene therapy company advancing “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported ...
November 5, 2018
Spring Bank Pharmaceuticals, Inc. to Present at Upcoming Healthcare Conferences
HOPKINTON, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral ...
November 5, 2018
Lipocine Announces Completion of Enrollment in LPCN 1144 Liver Imaging Study in Subjects At-Risk for NASH
SALT LAKE CITY, Nov. 5, 2018 /PRNewswire/ -- Lipocine Inc. (LPCN), a specialty pharmaceutical company, today announced the completion of enrollment in the proof-of-concept clinical study ...
November 5, 2018
AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 05, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
November 5, 2018
BioTime Receives Second Installment Payment of $10.8 Million From Juvenescence Ltd.
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has received the second installment payment ...
November 5, 2018
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
SANTA MONICA, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, ...
November 5, 2018
Tyme Provides Clinical and Corporate Update for Fiscal 2Q 2019
NEW YORK, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and ...
November 5, 2018
CohBar Provides Update on CB4211 Clinical Trial
MENLO PARK, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
November 5, 2018
Achaogen Announces Review of Strategic Alternatives and Corporate Restructuring
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Achaogen, Inc. (AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address ...
Page 6 of 117